Expanded Access to Glecaprevir/ Pibrentasvir
- Conditions
- Hepatitis C Virus Infection
- Registration Number
- NCT03123965
- Lead Sponsor
- AbbVie
- Brief Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Univ Medical Ctr Ljubljana /ID# 161419
🇸🇮Ljubljana, Slovenia